Aptose Biosciences Inc (LTS:0UI8)
C$ 1.33 0 (0%) Market Cap: 10.54 Mil Enterprise Value: 98,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

Aptose Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2022 / 07:35PM GMT
Release Date Price: C$111.3
Greg Renza
RBC Capital Markets, LLC - Analyst

Thank you and welcome back to the 2022 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotechnology equity research analysts here at RBC. And we're pleased today to be joined by Aptose Biosciences. And joining us from the company, Dr. Bill Rice, Chairman, President and Chief Executive Officer; and also joined by Dr. Bejar, the Chief Medical Officer of Aptose.

Gentlemen, thanks for joining us today. Great to see you in person. It's been a long time. And perhaps, Bill, I can just flip it to you to give a brief intro on Aptose, your two lead assets, the changes that have really elapsed and the path forward for the company.

Bill Rice
Aptose Biosciences Inc. - Chairman of the Board, President & CEO

All right, will do. Well, thanks for the invitation to your fireside chat. And in return, we will recommend you come to San Diego for a fire pit chat with margaritas. So we'll have to do that soon.

Okay. So a little bit of a background on Aptose. So this is a clinical-stage

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot